Fig. 2From: Effectiveness and safety of vedolizumab induction with or without budesonide in patients with moderately to severely active Crohn’s disease in Europe: a retrospective observational studyClinical remission rates at week 14. VDZ = vedolizumab; BUD = budesonideBack to article page